B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma

Scott E. Strome; Haidong Dong; Hideto Tamura; Stephen G. Voss; Dallas B. Flies; Koji Tamada; Diva Salomao; John Cheville; Fumiya Hirano; Wei Lin; Jan L. Kasperbauer; Karla V. Ballman; Lieping Chen

B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma

Scott E. Strome, Haidong Dong, Hideto Tamura, Stephen G. Voss, Dallas B. Flies, Koji Tamada, Diva Salomao, John Cheville, Fumiya Hirano, Wei Lin, Jan L. Kasperbauer, Karla V. Ballman, Lieping Chen

Research output: Contribution to journal › Article › peer-review

415 Scopus citations

Abstract

In this report, we demonstrate that B7-H1, a B7 family molecule implicated in tumor immune evasion, is constitutively expressed on 66% of freshly isolated squamous cell carcinomas of the head and neck (SCCHN). To define the potential impact of tumor-associated B7-H1 on immunotherapy, the B7-H1-negative mouse SCC line, SCCVII, was transfected to express B7-H1. Although all of the animals succumbed to B7-H1/SCCVII tumors even after adoptive T-cell immunotherapy, the infusion of B7-H1 blocking monoclonal antibody with activated T cells cured 60% of animals. These data support B7-H1 blockade as a new approach to enhance the efficacy of T-cell immunotherapy.

Original language	English (US)
Pages (from-to)	6501-6505
Number of pages	5
Journal	Cancer Research
Volume	63
Issue number	19
State	Published - Oct 1 2003
Externally published	Yes

ASJC Scopus subject areas

Cancer Research
Oncology

Cite this

@article{7d9c233ee3fe421f919f2af431aba442,

title = "B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma",

abstract = "In this report, we demonstrate that B7-H1, a B7 family molecule implicated in tumor immune evasion, is constitutively expressed on 66% of freshly isolated squamous cell carcinomas of the head and neck (SCCHN). To define the potential impact of tumor-associated B7-H1 on immunotherapy, the B7-H1-negative mouse SCC line, SCCVII, was transfected to express B7-H1. Although all of the animals succumbed to B7-H1/SCCVII tumors even after adoptive T-cell immunotherapy, the infusion of B7-H1 blocking monoclonal antibody with activated T cells cured 60% of animals. These data support B7-H1 blockade as a new approach to enhance the efficacy of T-cell immunotherapy.",

author = "Strome, {Scott E.} and Haidong Dong and Hideto Tamura and Voss, {Stephen G.} and Flies, {Dallas B.} and Koji Tamada and Diva Salomao and John Cheville and Fumiya Hirano and Wei Lin and Kasperbauer, {Jan L.} and Ballman, {Karla V.} and Lieping Chen",

year = "2003",

month = oct,

day = "1",

language = "English (US)",

volume = "63",

pages = "6501--6505",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "19",

}

TY - JOUR

T1 - B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma

AU - Strome, Scott E.

AU - Dong, Haidong

AU - Tamura, Hideto

AU - Voss, Stephen G.

AU - Flies, Dallas B.

AU - Tamada, Koji

AU - Salomao, Diva

AU - Cheville, John

AU - Hirano, Fumiya

AU - Lin, Wei

AU - Kasperbauer, Jan L.

AU - Ballman, Karla V.

AU - Chen, Lieping

PY - 2003/10/1

Y1 - 2003/10/1

N2 - In this report, we demonstrate that B7-H1, a B7 family molecule implicated in tumor immune evasion, is constitutively expressed on 66% of freshly isolated squamous cell carcinomas of the head and neck (SCCHN). To define the potential impact of tumor-associated B7-H1 on immunotherapy, the B7-H1-negative mouse SCC line, SCCVII, was transfected to express B7-H1. Although all of the animals succumbed to B7-H1/SCCVII tumors even after adoptive T-cell immunotherapy, the infusion of B7-H1 blocking monoclonal antibody with activated T cells cured 60% of animals. These data support B7-H1 blockade as a new approach to enhance the efficacy of T-cell immunotherapy.

AB - In this report, we demonstrate that B7-H1, a B7 family molecule implicated in tumor immune evasion, is constitutively expressed on 66% of freshly isolated squamous cell carcinomas of the head and neck (SCCHN). To define the potential impact of tumor-associated B7-H1 on immunotherapy, the B7-H1-negative mouse SCC line, SCCVII, was transfected to express B7-H1. Although all of the animals succumbed to B7-H1/SCCVII tumors even after adoptive T-cell immunotherapy, the infusion of B7-H1 blocking monoclonal antibody with activated T cells cured 60% of animals. These data support B7-H1 blockade as a new approach to enhance the efficacy of T-cell immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0141953992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141953992&partnerID=8YFLogxK

M3 - Article

C2 - 14559843

AN - SCOPUS:0141953992

SN - 0008-5472

VL - 63

SP - 6501

EP - 6505

JO - Cancer Research

JF - Cancer Research

IS - 19

ER -

B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this